DCDP
Financiado
Digital Cancer Diagnosis Platform
Chromition have developed innovative and disruptive digital cancer diagnostic platform. The platform uses Chromition’s innovative Luminspheres™ nanotechnology combined with spatial pattern recognition software to diagnose cancer....
Chromition have developed innovative and disruptive digital cancer diagnostic platform. The platform uses Chromition’s innovative Luminspheres™ nanotechnology combined with spatial pattern recognition software to diagnose cancer.
Luminspheres™ are multicoloured fluorescent nanoparticles that are prepared from carbon-based precursors in water at low temperature using our proprietary and environmentally considerate process.
Luminspheres™ bioimaging probes when tethered to biological molecules of interest provide sensitive and non-invasive insight into biological processes and interactions with minimal impact on the system under investigation.
Chromition are working with the Manchester University NHS Foundation Trust (MFT), using the Luminspheres™-antibody biomarker conjugates to stain tissue samples. The tissue samples are then analysed by Chromition’s digital platform, which is able to analyse multiple biomarkers in a short space of time using bespoke spatial pattern recognition software.
Chromition will use Luminspheres™ in Immunohistochemical Staining (IHC) to rapidly identify multiple biomarkers in a single image. The image will then be analysed by innovative software that facilitates fast and autonomous analysis of multiple samples across a clinical cohort.
The development of this technology will enable the identification and analysis of multiple biomarkers at a speed not currently possible using existing technology and relying on human sight.
The success of this project has the potential to transform the way clinical pathology is practiced.
In this project the platform will be used to identify multiple cancer biomarkers in tissue samples from women with endometrial cancers.
Utilising the Chromition method firstly for the identification of endometrial cancers, and using the results to tailor medical intervention, will have a significant impact on the cancer burden for women in the EU and globally.
ver más
Duración del proyecto: 6 meses
Fecha Inicio: 2018-11-20
Fecha Fin: 2019-05-31
Fecha Fin: 2019-05-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2019-05-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
CHROMITION LIMITED
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
419.83K€ |
Participante